3974-16-1

Basic information

• Product Name: PyriMidine, 4,6-dichloro-5-phenyl-
• Synonyms: PyriMidine, 4,6-dichloro-5-phenyl-;4,6-dichloro-5-phenylpyrimidine;5-(phenyl)-4,6-dichloropyrimidine
• CAS NO: 3974-16-1
• Molecular Formula: C₁₀H₆Cl₂N₂
• Molecular Weight: 225.07404
• Mol File: 3974-16-1.mol
• Article Data: 5

Chemical Properties

• Melting Point: 109 °C
• Boiling Point: 321.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.363±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -4.59±0.26(Predicted)
• CAS DataBase Reference: PyriMidine, 4,6-dichloro-5-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: PyriMidine, 4,6-dichloro-5-phenyl-(3974-16-1)
• EPA Substance Registry System: PyriMidine, 4,6-dichloro-5-phenyl-(3974-16-1)

Safety Data

• Hazardous Substances Data: 3974-16-1(Hazardous Substances Data)

Usage

General Description

Pyrimidine, 4,6-dichloro-5-phenyl- is a chemical compound with the molecular formula C10H6Cl2N2. It is a derivative of pyrimidine, which is a heterocyclic aromatic organic compound. This specific derivative contains two chlorine atoms and a phenyl group attached to the pyrimidine ring structure. It is used in various fields, including pharmaceuticals, agrochemicals, and materials science. The compound has been studied for its potential biological activities, including antifungal and antiviral properties. Additionally, it has been investigated for its role as a building block in the synthesis of novel organic compounds for various applications.

Upstream product

• 18337-64-9 5-phenylpyrimidine-4,6-diol 
• 103-82-2 phenylacetic acid 
• 101-41-7 benzeneacetic acid methyl ester 
• 64415-11-8 4,6-dichloro-2-methylthio-5-phenylpyrimidine 
• 1312466-27-5 4,6-dichloro-2-(methylsulfonyl)-5-phenylpyrimidine 
• 83-13-6 diethyl 2-phenylmalonate 

Downstream Products

• 1312466-07-1 6-chloro-5-phenylpyrimidine-4-(9-O-quinidine) ether 
• 441797-36-0 C₁₇H₁₅ClN₄O₂S 
• 917395-99-4 4-chloro-6-(4-chlorophenyl)-5-phenylpyrimidine 
• 14630-97-8 dimethyl-(6-phenothiazin-10-yl-5-phenyl-pyrimidin-4-yl)-amine 
• 335063-11-1 4-chloro-6-[4-(5-methyl-1H-imidazol-4-yl)-piperidin-1-yl]-5-phenyl-pyrimidine 
• 14630-96-7 10-(6-chloro-5-phenyl-pyrimidin-4-yl)-10H-phenothiazine 

Relevant articles and documents

The discovery of N -[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy] ethoxy]-4-pyrimidinyl]- N ′-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist

Starting from the structure of bosentan (1), we embarked on a medicinal chemistry program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy. This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines. Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ET B receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats. Compound 17 successfully completed a long-term phase III clinical trial for pulmonary arterial hypertension.

4-Amino-5-aryl-6-arylethynylpyrimidines: Structure-activity relationships of non-nucleoside adenosine kinase inhibitors

A series of non-nucleoside adenosine kinase (AK) inhibitors is reported. These inhibitors originated from the modification of 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-ylamine (ABT-702). The identification of a linker that would approximate the spatial arrangement found between the pyrimidine ring and the aryl group at C(7) in ABT-702 was a key element in this modification. A search of potential linkers led to the discovery of an acetylene moiety as a suitable scaffold. It was hypothesized that the aryl acetylenes, ABT-702, and adenosine bound to the active site of AK (closed form) in a similar manner with respect to the orientation of the heterocyclic base. Although potent acetylene analogs were discovered based on this assumption, an X-ray crystal structure of 5-(4-dimethylaminophenyl)-6-(6-morpholin-4-ylpyridin-3-ylethynyl)pyrimidin-4-ylamine (16a) revealed a binding orientation contrary to adenosine. In addition, this compound bound tightly to a unique open conformation of AK. The structure-activity relationships and unique ligand orientation and protein conformation are discussed.

Heterocyclic sodium/proton exchange inhibitors and method

Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C—R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl gorup, R1, R2, R3 and R4 are as defined herein, and where X is N. R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.